Restricted accessResearch articleFirst published online 2019-04
Comparison of Dendritic Cell Activation by Virus-Based Vaccine Delivery Vectors Emphasizes the Transcriptional Downregulation of the Oxidative Phosphorylation Pathway
Antigen delivery platforms based on engineered viruses or virus-like particles are currently developed as vaccines against infectious diseases. As the interaction of vaccines with dendritic cells (DCs) shapes the immunological response, we compared the interaction of a range of virus-based vectors and virus-like particles with DCs in a murine model of systemic administration and transcriptome analyses of splenic DCs. The transcriptome profiles of DCs separated the vaccine vectors into two distinct groups characterized by high- and low-magnitude differential gene expression, which strongly correlated with (1) the surface expression of costimulatory molecules CD40, CD83, and CD86 on DCs, and (2) antigen-specific T-cell responses. Pathway analysis using PANOGA (Pathway and Network-Oriented GWAS Analysis) revealed that the JAK/STAT pathway was significantly activated by both groups of vaccines. In contrast, the oxidative phosphorylation pathway was significantly downregulated only by the high-magnitude DC-stimulating vectors. A gene signature including exclusively chemokine-, cytokine-, and receptor-related genes revealed a vector-specific pattern. Overall, this in vivo DC stimulation model demonstrated a strong relationship between the levels of induced DC maturation and the intensity of T-cell-specific immune responses with a distinct cytokine/chemokine profile, metabolic shifting, and cell surface expression of maturation markers. It could represent an important tool for vaccine design.
Get full access to this article
View all access options for this article.
References
1.
PulendranB, AhmedR. Immunological mechanisms of vaccination. Nat Immunol, 2011; 12(6):509–517.
2.
PlotkinSA. Complex correlates of protection after vaccination. Clin Infect Dis, 2013; 56:1458–1465.
3.
VerardiPH, TitongA, HagenCJ. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum Vaccin Immunother, 2012; 8:961–970.
4.
AppaiahgariMB, VratiS. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther, 2015; 15:337–351.
JennerRG, YoungRA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol, 2005; 3:281–294.
8.
BanchereauR, BaldwinN, CepikaAM, et al.Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines. Nat Commun, 2014; 5:5283.
9.
DerianN, BellierB, PhamHP, et al.Early transcriptome signatures from immunized mouse dendritic cells predict late vaccine-induced T-cell responses. PLoS Comput Biol, 2016; 12:e1004801.
10.
SzklarczykD, FranceschiniA, KuhnM, et al.The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res, 2011; 39:D561–D568.
11.
IdekerT, OzierO, SchwikowskiB, SiegelAF. Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics, 2002; 18(Suppl. 1):S233–S240.
12.
Bakir-GungorB, SezermanOU. A new methodology to associate SNPs with human diseases according to their pathway related context. PLoS One, 2011; 6:e26277.
13.
RitchieME, PhipsonB, WuD, et al.limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43:e47.
14.
SchroderMS, CulhaneAC, QuackenbushJ, Haibe-KainsB. survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics, 2011; 27:3206–3208.
15.
Haibe-KainsB, DesmedtC, SotiriouC, BontempiG. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics, 2008; 24:2200–2208.
16.
WickhamH.ggplot2, 1st ed. New York: Springer-Verlag; 2009.
17.
TeamR.RStudio: Integrated Development for R. Boston, MA: RStudio, Inc.; 2015. http://www.rstudio.com/.
18.
De SmedtT, PajakB, MurailleE, et al.Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med, 1996; 184:1413–1424.
19.
Reis e SousaC, HienyS, Scharton-KerstenT, et al.In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med, 1997; 186:1819–1829.
20.
SutterG, MossB. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A, 1992; 89:10847–10851.
PerkinsAS, KirschmeierPT, Gattoni-CelliS, WeinsteinIB. Design of a retrovirus-derived vector for expression and transduction of exogenous genes in mammalian cells. Mol Cell Biol, 1983; 3:1123–1132.
23.
FranzenAV, TegerstedtK, HollanderovaD, ForstovaJ, RamqvistT, DalianisT. Murine polyomavirus-VP1 virus-like particles immunize against some polyomavirus-induced tumours. In Vivo, 2005; 19:323–326.
24.
TissotAC, RenhofaR, SchmitzN, et al.Versatile virus-like particle carrier for epitope based vaccines. PLoS One, 2010; 5:e9809.
25.
StoverCK, de la CruzVF, FuerstTR, et al.New use of BCG for recombinant vaccines. Nature, 1991; 351:456–460.
26.
HollidayLS. Vacuolar H+-ATPase: an essential multitasking enzyme in physiology and pathophysiology. N J Sci, 2014; 2014:21.
27.
TrombettaES, EbersoldM, GarrettW, PypaertM, MellmanI. Activation of lysosomal function during dendritic cell maturation. Science, 2003; 299:1400–1403.
28.
TamuraT, YanaiH, SavitskyD, TaniguchiT. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol, 2008; 26:535–584.
29.
BarnesBJ, RichardsJ, ManclM, HanashS, BerettaL, PithaPM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem, 2004; 279:45194–45207.
30.
TamuraT, TailorP, YamaokaK, et al.IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol, 2005; 174:2573–2581.
31.
KrawczykCM, HolowkaT, SunJ, et al.Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood, 2010; 115:4742–4749.
32.
EvertsB, AmielE, van der WindtGJ, et al.Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood, 2012; 120:1422–1431.
33.
EvertsB, PearceEJ. Metabolic control of dendritic cell activation and function: recent advances and clinical implications. Front Immunol, 2014; 5:203.
34.
GkikasI, PalikarasK, TavernarakisN. The role of mitophagy in innate immunity. Front Immunol, 2018; 9:1283.
35.
CimicaV, GalarzaJM. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin Immunol, 2017; 183:99–108.
36.
Madan-LalaR, SiaJK, KingR, et al.Mycobacterium tuberculosis impairs dendritic cell functions through the serine hydrolase Hip1. J Immunol, 2014; 192:4263–4272.
37.
FujiiS, LiuK, SmithC, BonitoAJ, SteinmanRM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med, 2004; 199:1607–1618.
38.
GarroneP, FluckigerAC, MangeotPE, et al.A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med, 2011; 3:94ra71.
39.
KirchmeierM, FluckigerAC, SoareC, et al.Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol, 2014; 21:174–180.
40.
VBI Vaccines. VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine. 2018. https://www.vbivaccines.com/wire/cmv-vaccine-phase-1-study-results/.
41.
PitoisetF, VazquezT, LevacherB, et al.Retrovirus-based virus-like particle immunogenicity and its modulation by Toll-like receptor activation. J Virol, 2017; 91:e01230–17.
DelaloyeJ, RogerT, Steiner-TardivelQG, et al.Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog, 2009; 5:e1000480.
44.
PricePJ, Torres-DominguezLE, BrandmullerC, SutterG, LehmannMH. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine, 2013; 31:4231–4234.
45.
TatsisN, ErtlHC. Adenoviruses as vaccine vectors. Mol Ther, 2004; 10:616–629.
46.
HartmanZC, AppledornDM, AmalfitanoA. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res, 2008; 132:1–14.
47.
BellierB, DalbaC, ClercB, et al.DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine, 2006; 24:2643–2655.
48.
KaneM, CaseLK, WangC, YurkovetskiyL, DikiyS, GolovkinaTV. Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity, 2011; 35:135–145.
49.
PertelT, HausmannS, MorgerD, et al.TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature, 2011; 472:361–365.
50.
GeorgelP, JiangZ, KunzS, et al.Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology, 2007; 362:304–313.
51.
ChapmanR, ChegeG, ShephardE, StutzH, WilliamsonAL. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res, 2010; 8:282–298.
52.
QuesniauxV, FremondC, JacobsM, et al.Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect, 2004; 6:946–959.
53.
BaficaA, ScangaCA, FengCG, LeiferC, CheeverA, SherA. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. The J Exp Med, 2005; 202:1715–1724.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
